泽布替尼大卖26亿美元,百济神州亏损进一步收窄

国际金融报
28 Mar

3月27日盘后,创新药明星公司百济神州发布2024年全年业绩公告。财报数据显示,去年全年百济神州营收同比增长约55%至约38亿美元,其中产品收入增长72.6%至约38亿美元。亏损进一步收窄约26.9%至6.45亿美元。二级市场上,截至3月28日收盘,百济神州A股报收231.38元,跌0.12%;H股报收161.6港元,涨1.25%。泽布替尼大卖26亿美元具体来看,2024年为百济神州业绩“回血”的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10